Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

9 hours ago · Ratings for Moderna MRNA were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise …

$58
OFF

Moderna, Inc.: Target Price Consensus And Analysts …

2 weeks from now

2 days ago · Analyst recommendations: Biogen, HP, Moderna, Shell... Nov. 18: HSBC Upgrades Moderna to Buy From Hold, Adjusts Price Target to $58 From $82 Nov. 18: MT Deutsche …

marketscreener.com

$140.55
OFF

Demystifying Moderna: Insights From 11 Analyst Reviews

2 weeks from now

Aug 15, 2024 · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $140.55, with a high estimate of $214.00 and a low estimate …

nasdaq.com

$18
OFF

Moderna's MRNA Technology Looks Undervalued Despite Lower …

2 weeks from now

1 day ago · Moderna's massive covid vaccine sales and prepayments left it with $18.2 billion in cash at the end of 2022, but that balance is steadily shrinking due to previous share …

morningstar.com

94%
OFF

Moderna Stock Has Lost 94% Of Its Value Over Four Years. Is It A …

2 weeks from now

1 day ago · Moderna Stock's Bearish Ratings Moderna stock is showing bearish fundamentals and technicals. First, shares are trading below their 50-day and 200-day moving averages, …

investors.com

$10.75
OFF

Is Moderna Stock A No-Brainer Buy On The Sell-Off?

2 weeks from now

1 day ago · However, Moderna's enterprise value (EV) is $10.75 billion -- lower than its market cap thanks to a hefty cash stockpile and manageable debt load. If the company can generate …

fool.com

$85
OFF

Fortive Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

2 weeks from now

1 day ago · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $85.8, a high estimate of $95.00, and a low estimate of $77.00.

benzinga.com

$182.85
OFF

What 13 Analyst Ratings Have To Say About Moderna

2 weeks from now

In the last 3 months, 13 analysts have offered 12-month price targets for Moderna. The company has an average price target of $182.85 with a high of $275.00 and a low of $93.00.

businessinsider.com

$69.25
OFF

Moderna Options Trading: A Deep Dive Into Market Sentiment

2 weeks from now

Nov 6, 2024 · Professional Analyst Ratings for Moderna A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $69.25. …

nasdaq.com

$14.09
OFF

Deep Dive Into Snap Stock: Analyst Perspectives (18 Ratings)

2 weeks from now

1 day ago · Insights from analysts' 12-month price targets are revealed, presenting an average target of $14.09, a high estimate of $17.00, and a low estimate of $9.00.

benzinga.com

$2
OFF

Deep Dive Into US Energy Stock: Analyst Perspectives (4 Ratings)

2 weeks from now

2 days ago · The 12-month price targets, analyzed by analysts, offer insights with an average target of $2.0, a high estimate of $2.00, and a low estimate of $2.00.

nasdaq.com

$338.57
OFF

Visa Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)

2 weeks from now

1 day ago · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $338.57, a high estimate of $375.00, and a low estimate of $292.00.

benzinga.com

$32.67
OFF

Deep Dive Into CNX Resources Stock: Analyst Perspectives (9 …

2 weeks from now

10 hours ago · In the assessment of 12-month price targets, analysts unveil insights for CNX Resources, presenting an average target of $32.67, a high estimate of $38.00, and a low …

nasdaq.com

$106
OFF

Deep Dive Into ONEOK Stock: Analyst Perspectives (10 Ratings)

2 weeks from now

6 days ago · Insights from analysts' 12-month price targets are revealed, presenting an average target of $106.6, a high estimate of $132.00, and a low estimate of $98.00.

benzinga.com

$53
OFF

Archer-Daniels Midland Stock: A Deep Dive Into Analyst …

2 weeks from now

1 day ago · In the assessment of 12-month price targets, analysts unveil insights for Archer-Daniels Midland, presenting an average target of $53.6, a high estimate of $56.00, and a low …

nasdaq.com

FAQs about Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings) Coupon?

How do analysts evaluate Moderna (Moderna) stock?

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Moderna's stock. ...

How many analysts downgraded Moderna stock on Thursday?

Five analysts out of 25 downgraded Moderna stock on Thursday, according to FactSet. And 14 cut their price targets on shares. Moderna stock tumbled 2% to 68.28 on Friday. That followed a 12.4% dive on Thursday. It's not the first time Moderna's financial outlook has weighed on shares, William Blair analyst Myles Minter said. ...

What is the average price target for Moderna?

The 12-month price targets, analyzed by analysts, offer insights with an average target of $147.3, a high estimate of $214.00, and a low estimate of $106.00. This current average has increased by 4.01% from the previous average price target of $141.62. An in-depth analysis of recent analyst actions unveils how financial experts perceive Moderna. ...

How do analysts evaluate Moderna's stock?

Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Moderna's stock. This comparison reveals trends in analysts' expectations over time. Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Moderna's market standing. ...

How do analysts evaluate Moderna's performance?

Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts predict movements in price targets, offering estimates for Moderna's future value. ...

What is Moderna mRNA technology?

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. ...